Oxytocin, a possible treatment for COVID-19? EVERYTHING TO GAIN, NOTHING TO LOSE. Letter to the editor. From the editor’desk. Commentary.

  • Version
  • Issue
  • [published] Published:
  • doi.org/10.36131/CNEPUB20201703 DOI
  • Competing Interests: Patents in which Kerstin Uvnäs Moberg is an inventor EP2696882A1 PHARMACEUTICAL COMPOSITION (active) US2006148685A1 Use of substances with oxytocin activity against climacteric disorders (active) EP1115416A1 USE OF SUBSTANCES WITH OXYTOCINACTIVITY IN ORDER TO CREATE CELL REGENERATION (Time has run out) WO9843660A1 USE OF SUBSTANCES HAVING OXYTOCIN ACTIVITY FOR PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF AFFECTIVE PAIN SYNDROMES (Time has run out) All patents owned by the company Peptonic Medical. Kerstin Uvnäs Moberg is not employed by Peptonic Medical and no studies with oxytocin are presently being performed. Kerstin Uvnäs Moberg owns 2% of the stock in Peptonic Medical.
  • 91 Download
  • 797.47 KB File Size

Phuoc-Tan Diep, Benjamin Buemann, Kerstin Uvnäs-Moberg. Donatella Marazziti. C. Sue Carter


Download
FileAction
1592484683wpdm_2020-02-03_Letter_Commentary.pdfDownload